London-listed Scancell (AIM:SCLP) says momentum is building after signing a deal for its proprietary AvidiMab™ technology with an unnamed US-based antibody firm.
This marks the third collaborative agreement for the developer of novel immunotherapies for the treatment of cancer and follows two prior deals inked in September 2019 and December 2019, respectively.
Under the deal, research will include an evaluation of Scancell's pipeline of anti-TaG mAbs to target tumour cells which have been engineered using the Company's AvidiMab™ technology.
Shares in Scancell Holdings reacted positively and were trading 14.40% higher at 7.15p on Monday morning.
AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies -- this means inducing monoclonal antibodies (mAbs) with direct tumour cell killing properties to target TaGs, tumour-associated glycans.
“This continued momentum with AvidiMab™ and our tumour-associated glycan antibodies demonstrates the growing excitement around this platform,” said Dr Cliff Holloway, Chief Executive of Scancell.
The group highlighted the platform's ‘broad potential’ to optimise any therapeutic monoclonal antibody including those being developed for autoimmune diseases as well as cancer.
The company views the collaboration as significant for extracting future value via the potential of this third platform, added Holloway.
Separately, Scancell is currently developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
Follow News & Updates from Scancell Holdings here: